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ABSTRACT 
The etiology of Parkinson’s disease (PD) is largely unknown, but epidemiological studies 
have provided robust evidence that environmental factors have a central role in PD 
pathogenesis and progression. The studies included in this thesis examined associations 
between several lifestyle factors and subsequent risk of PD. 
 
In study I, we prospectively investigated the association between physical activity and risk of 
PD in a Swedish cohort of 43,368 men and women. We found that higher levels of physical 
activity were associated with lower risk of PD. In addition, when pooling our results and all 
previously prospective cohort studies on this topic using meta-analysis, there was a 34% 
lower risk of PD for the highest level of physical activity compared with the lowest level. 
 
In the second study (study II), we examined the effect of Swedish moist smokeless tobacco 
(i.e. snus in Swedish) on future risk of PD using individual participant data from seven 
Swedish cohorts, consisting of 348,601 men. Our pooled results confirmed that non-smoking 
men who used snus had a substantially lower risk of PD compared with never snus users. In 
addition, a dose-response relationship between snus use and risk of PD was indicated. 
 
A third series of analyses evaluated the effect of dietary antioxidants on PD risk (study III). 
Using comprehensive dietary information on 45,837 men and 38,937 women from two 
population-based cohorts, we concluded that intake of dietary vitamin E and β-carotene was 
associated with a lower risk of PD. 
 
In the last study (study IV), we analyzed Swedish census data with more than 4.6 million 
individuals regarding the potential effect of socioeconomic status on PD risk, as well as all-
cause mortality before and after PD diagnosis. PD risk was higher in individuals with higher 
socioeconomic status, and all-cause mortality was higher in individuals with lower 
socioeconomic status regardless of PD status. However, the impact of socioeconomic status 
on all-cause mortality was weaker in PD patients than in PD-free individuals. 
 
In conclusion, our findings contribute to the existing epidemiological evidence on the 
associations between lifestyle factors and risk of PD. Our results from prospective cohort 
studies suggest that lifestyle factors can influence future risk of PD. Interventions on these 
lifestyle factors may have the possibility to prevent the disease eventually. 
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1 INTRODUCTION 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the 
world, topped by Alzheimer’s disease. PD is a complex movement disorder that results in 
primarily motor dysfunction, but non-motor symptoms are also common. The disease was 
first clinically described in detail by the London doctor, James Parkinson, 200 years ago in 
his landmark “An Essay on the Shaking Palsy”.1 In this essay, Parkinson defined the shaking 
palsy as a combination of rest tremor, lessened muscular power, abnormal truncal posture, 
and festinant and propulsive gait.
2
 These features are still used today to establish a diagnosis 
of PD clinically. In particular, he documented six illustrative cases of PD, though these 
observed cases were actually a mixture of different disorders according to current knowledge 
of neurology.  
 
Undoubtedly, Parkinson’s monograph encourages other doctors to advance the knowledge of 
the disease, yet both the essay and Parkinson himself received little immediate attention in 
British medical circles at the time.
3
 About 60 years later, a French neurologist Jean Martin 
Charcot distinguished slowness of movement from weakness and added other clinical 
manifestations to the description of the disease, including non-tremulous form and facial 
motor involvement. In fact, Charcot was the first who acknowledged the significance of 
Parkinson’s essay and named the disease after him.4 
 
At the time of Parkinson’s essay, there was no effective treatment for the disease. There is 
still no cure today. It is also unclear when people start developing PD since mechanisms of 
the disease are unknown. However, the interest of the scientific community in PD is 
constantly growing, triggered by recent discoveries from genetic studies.
5
 Indeed, genetic 
findings may pinpoint potential pathogenesis and etiology of the disease,
6
 but they only 
explain a small fraction of the disease since over 90% of PD cases are sporadic with no 
identifiable genetic cause.
7
 
 
Observational findings have provided compelling evidence on behavioral and environmental 
factors in relation to PD,
8
 with the most robust finding being an inverse association between 
smoking and risk of PD. As a result, other lifestyle aspects such as physical activity and diet 
have been suggested to play an important role to further the understanding of the 
pathogenesis and progression of PD. Large, well-designed and population-based 
 2 
epidemiological prospective cohort studies are probably the best ways to investigate potential 
risk factors for PD, as well as the outcomes that develop during a long period of the disease.
9
 
 
In this thesis, I provide an update on the epidemiological evidence of PD along with four 
epidemiological studies that I conducted during the period of my PhD studies, focusing on 
four specific lifestyle factors. PD refers to idiopathic PD unless specified otherwise. 
Epidemiological studies regarding potential genetic causes of PD or 
parkinsonism/Parkinsonian disorders other than PD are briefly mentioned but fall beyond the 
scope of this thesis. 
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2 BACKGROUND 
PD involves both the dopamine system and Lewy pathology. In the central nervous system 
(CNS), dopamine functions as a neurotransmitter sending signals from one neuron to another. 
In the brain, the dopamine system includes several pathways that play important roles in 
neuronal activities, for example the nigrostriatal pathway that is responsible for motor 
control. More specifically, patients with PD have substantial loss of dopaminergic neurons 
(i.e. dopamine-secreting neurons) in the substantia nigra parts compacta (SNpc) located in the 
mesencephalon (i.e. midbrain of the brainstem). These dopaminergic neurons project to the 
striatum of the basal ganglia, which interconnect with other brain areas including the motor 
cortex (frontal lobe). The cell death of dopaminergic neurons leads to depletion of dopamine 
in the striatum, resulting in motor dysfunction. 
 
In addition to dysfunction of the dopaminergic system, PD is associated with presence of 
ubiquinated misfolded proteins (i.e. α-synuclein) in the cytoplasm of neurons.10 In the 
misfolded situation, the soluble protein α-synuclein aggregates abnormally and becomes 
insoluble to form intracellularly spherical inclusions, called Lewy bodies and Lewy 
neurites.
11
 Lewy bodies are found extensively in dopaminergic neuros of SNpc in patients 
with PD, but also in other parts of the CNS. Based upon this observation of Lewy bodies in 
PD patients, Braak and colleagues proposed a hypothesis that the Lewy pathology starts from 
peripheral nervous system and progresses to the CNS in a caudal-to-rostral direction.
12
 The 
Lewy pathology in PD includes six stages (Table 1.1). Although it is still controversial, the 
Braak staging seems to explain largely the clinical course of PD. 
 
Table 1.1 Braak staging of Lewy pathology in PD (adapted from Braak et al.
12
) 
Stage 1 
 Lesions found in the peripheral nervous system (autonomic neurons), olfactory system, and 
medulla (dorsal motor nuclei of vagal and glossopharyngeal nerves) 
Stage 2 
 Caudal raphe nuclei, gigantocellular reticular nucleus, and coeruleus–subcoeruleus complex 
Stage 3 
 Midbrain (substantia nigra pars compacta) 
Stage 4 
 Anteromedial temporal mesocortex, thalamus, and limbic system (accessory cortical and 
central nuclei of amygdala, and ventral claustrum) 
Stage 5 
 High order sensory association areas and prefrontal areas (anterior cortex) 
Stage 6 
 First order sensory association and premotor areas, as well as primary sensory and motor areas. 
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2.1 Symptoms and Diagnosis of Parkinson’s Disease 
2.1.1 Symptoms of Parkinson’s disease 
PD is the most common (about 80%) neurodegenerative cause of parkinsonism, which is a 
clinical syndrome and includes other parkinsonian disorders such as cerebrovascular 
parkinsonism and multiple system atrophy, etc. The symptoms of PD are characterized by 
three cardinal motor dysfunctions: 
 
 Tremor (shaking) 
An involuntary shaking movement in a part of the body. In comparison to an 
“essential tremor/action tremor” that happens during the action of movement, 
patients with PD are more likely to have a “resting tremor”, which happens when the 
body is relaxed, such as sitting down with hands resting on the lap.  
 
 Bradykinesia (Slowness of movement) 
Slowness of movement during, for example, walking or using hands and arms. 
Patients with PD may find it takes longer to do regular things, such as turning around, 
getting out of chairs, or writing. 
 
 Rigidity (stiffness or inflexible muscles) 
Stiffness of muscles and joints of the body.  
 
These motor symptoms start slowly and develop gradually with no particular order. They 
usually begin in one hand and spread to limbs on the same side, then to the other side of the 
body. Notably, resting tremor can be the first noticeable sign of PD. However, tremor may be 
caused by other conditions, and not all PD patients develop the resting tremor.  
 
In addition, modern symptomatology of PD considers PD heterogeneous meaning that the 
disease pathology involves multiple regions of the nervous system, several neurotransmitters, 
and different protein aggregates besides the Lewy bodies. Thus, non-motor symptoms are 
also of clinical significance to patients with PD. Moreover, non-motor features have been 
suggested as early clinical manifestations of PD for up to 20 years prior to the occurrence of 
cardinal motor symptoms (Figure 1.1). Such non-motor features include olfactory 
dysfunction, cognitive impairment, psychiatric symptoms, sleep disorders, fatigue, and 
others. 
 5 
 
 
 
Figure 1.1 Clinical symptoms and time course of Parkinson’s disease progression (Reprinted from 
Kalia LV & Lang AE,
6
 with permission from Elsevier) 
A premotor or prodromal phase of PD (characterized by specific non-motor symptoms) can be 20 years or more 
prior to PD diagnosis made at the onset of motor symptoms (time 0 years). EDS = excessive daytime sleepiness; 
MCI = mild cognitive impairment; RBD = REM sleep behavior disorder. 
 
 
2.1.2 Diagnosis of Parkinson’s disease 
There is no biological marker for the diagnosis of PD. At present, a clinical diagnosis of PD 
relies on motor symptoms and definite PD depends on post-mortem neuropathological 
examination. Several clinical diagnostic criteria for PD have been proposed.
13-17
 The most 
commonly used criteria by physicians are the UK Parkinson’s disease Society Brain Bank 
Clinical Diagnostic Criteria (UK-Criteria, Table 1.2). 
 
The UK-Criteria were suggested more than 20 years ago. As the understanding of PD 
advances, the UK-Criteria are thought to be insufficient for the clinical research requirements 
nowadays.
18
 Therefore, the Movement Disorder Society refined the UK-Criteria and 
presented the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s 
Disease (MDS-PD Criteria) in 2015 to replace the UK-Criteria for use in clinical research 
and potentially in the clinical setting.
19
 The MDS-PD Criteria reinforce the importance of 
early non-motor manifestations compared to the UK-Criteria,
20
 yet they have not been 
validated for accuracy against the definite diagnosis of PD. Nevertheless, MDS-PD criteria 
reported higher sensitivity than the UK-Criteria.
21
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Table 1.2 UK Parkinson’s disease Society Brain Bank Clinical Diagnostic Criteria (adapted from 
Hughes et al.
17
) 
Step 1: Inclusion criteria for possible PD 
 Bradykinesia (Slowness of initiation of voluntary movement with progressive reduction in 
speed and amplitude of repetivtive actions) 
 And at least one of the following: 
Muscular rigidity 
4-6 Hz rest tremor 
Postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive 
dysfunction 
Step 2: Exclusion criteria for PD 
 History of repeated strokes with stepwise progression of parkinsonian features 
 History of repeated head injury 
 History of definite encephalitis 
 Oculogyric crises 
 Neuroleptic treatment at onset of symptoms      
 More than one affected relative   
 Sustained remission 
 Strictly unilateral features after 3 years 
 Supranuclear gaze palsy 
 Cerebellar signs 
 Early severe autonomic involvement 
 Early severe dementia with disturbances of memory, language, and praxis 
 Babinski sign 
 Presence of cerebral tumour or communicating hydrocephalus on CT scan 
 Negative response to large doses of levodopa (if malabsorption excluded) 
 MPTP exposure 
Step 3: Supportive prospective positive criteria for diagnosis of definite PD 
(Three or more required) 
 Unilateral onset 
 Rest tremor present 
 Progressive disorder 
 Persistent asymmetry affecting side of onset most 
 Excellent response (70–100%) to levodopa 
 Severe levodopa-induced chorea 
 Levodopa response for 5 years or more 
 Clinical course of 10 years or more 
 
PD = Parkinson’s disease; CT = computed tomography; MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 
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2.2 Prevalence, Incidence and Mortality of Parkinson’s Disease 
The overall prevalence of PD was estimated at 0.3% for all ages and at 1% for people over 60 
years of age in high-income countries.
9
 A slightly increased prevalence of PD was found in 
men than in women.
22
 Importantly, age is the greatest contributor to the development of PD, 
since the disease occurs rarely before age 50 and the prevalence can reach up to 1,903 per 
100,000 in individuals over the age of 80.
22
 Compared to developed countries, prevalence of 
PD seems to be lower in developing countries, where prevalence for all ages was estimated at 
10-43 per 100,000, 15-119 per 100,000, and 27-43 per 100,000 in Asian, African, and Arabic 
countries, respectively.
6
 
  
Prevalence of a disease is prone to bias such as differences in survival among various age 
groups, whereas incidence rate is theoretically not affected by survival and therefore a better 
measure of the risk of disease.
23
 Overall, incidence rates of PD estimated for all ages range 
from 1.5 to 22 per 100,000 person-years (PYR).
24
 Similar to the prevalence, the incidence of 
PD increases rapidly with age, especially after 60 years of age and it peaks at around 80 years 
of age.
25
 Age-standardized incidence of PD was estimated at between 16 and 19 per 100,000 
PYR.
26
 In high-income countries such as the United States, median age-standardized 
incidence of PD was estimated at 14/100,000 PYR in the total population and up to 
160/100,100 PYR for individuals over the age of 65.
27
 Men seemed to have a higher risk of 
PD than women, with the male-to-female incidence ratio ranging from around 1.3 to 2.0.
28,29
 
Similarly, cumulative incidence of PD adjusted for competing risk of death (i.e. lifetime risk 
of PD), was higher in men (2%) than in women (1.3%).
30
 
 
Patients with PD have a shorter life expectancy than healthy individuals. Most 
epidemiological studies suggested mortality hazard ratios (HR) at about 2 (ranging between 
1.3 and 5.7) for patients with PD compared to the general population.
24
  
 
 
2.3 Risk Factors for Parkinson’s Disease 
The exact cause of PD is largely unknown, but risk factors proposed for the development of 
PD include both genetic and non-genetic/environmental factors. 
 
 
 8 
2.3.1 Genetic factors 
A genetic component in PD was suggested by discoveries of monogenic forms of PD (Table 
1.3).
31-34
 In addition, a heritability estimate of 34% was suggested in a previous twin study
35
 
but others reported low concordance rates in monozygotic and dizygotic twins,
36-40
 
suggesting the importance of non-genetic or environmental factors in PD etiology. A recent 
meta-analysis reported a higher risk of PD [relative risk (RR): 2.9, 95% confidence interval 
(CI): 2.2-3.8] for having a first-degree relative with PD.
41
  
 
Although highly penetrant monogenic mutations have been identified, these findings were 
primarily based on family data, whereas most PD patients (90%) are sporadic cases.
7
 Thus, 
environmental factors may play an important role in the etiology of sporadic PD. 
 
 
 
Table 1.3 Monogenic forms of Parkinson’s disease, by gene (Adapted from Kalia LV & Lang AE,6 
with permission from Elsevier) 
 Protein Pathogenic mutation(s) 
Autosomal dominant 
 
SNCA α-synuclein Missense mutations (Ala18Thr, Ala29Ser, 
Ala30Pro, Glu46Lys, His50Gln, Gly51Asp, 
Ala53Glu, Ala53Thr); multiplications 
(duplications, triplications) 
LRRK2 Leucine-rich repeat kinase 2 Missense mutations (Ile1371Val, Asn1437His, 
Arg1441Cys, Arg1441Gly, Arg1441His, 
Tyr1699Cys, Gly2019Ser [most common], 
Ile2020Thr) 
VPS35 Vacuolar protein sorting 35 Missense mutation (Asp620Asn) 
EIF4G1 Eukaryotic translation initiation 
factor 4-γ 1 
Missense mutations (Arg1205His, Ala502Val) 
DNAJC13 Receptor-mediated endocytosis 8 
(REM-8) 
Missense mutation (Asn855Ser) 
CHCHD2 Coiled-coil-helix-coiled-coil-helix 
domain containing 2 
Missense mutations (Thr61Ile, Arg145Gln); 
splice-site alteration 
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(Table 3 Continued) 
 
Autosomal recessive 
 
Parkin Parkin Exon rearrangements, including exon deletions 
or multiplications (most common); missense 
mutations, nonsense mutations, small deletions 
or insertions; splice-site alterations 
PINK1 PTEN-induced putative kinase 1 Missense or nonsense mutations (most 
common); exon rearrangements, including 
exon deletions or duplications 
DJ-1 DJ-1 Missense mutations or exon rearrangements 
(most common); splice-site alterations 
 
 
 
2.3.2 Non-genetic/Environmental factors 
Compared with genetic studies, associations between non-genetic/environmental factors and 
risk of PD were consistently observed in epidemiological research.
42
 Four specific lifestyle 
factors primarily investigated in this thesis are introduced below. 
 
 
2.3.2.1 Physical activity 
Physical activity is defined as “any bodily movement produced by skeletal muscles resulting 
in energy expenditure”.43 It is a multidimensional behavior that includes different forms of 
activities of the body as long as it results in energy expenditure. Physical exercise is a type of 
physical activity that is planned, structured and repetitive for the purpose of improvement or 
maintenance of the body.
43
  
 
Total energy expenditure of the human body can be divided into three parts: basal metabolic 
rate (BMR), diet induced thermogenesis, and physical activity. BMR, the rate at which the 
body metabolizes energy in order to stay alive, is a function of both body size and 
composition, and is affected mainly by age, gender, weight and height.
44
 BMR accounts for 
around 60-75% of total energy expenditure. Diet induced thermogenesis is the energy 
required to digest food and absorb nutrients, accounting for about 10% of total energy 
expenditure. These two parts are rather stable compared to physical activity. Physical activity 
is the most modifiable part of the total energy expenditure. 
 10 
 
Measurement of physical activity 
Energy expenditure from physical activity varies by frequency, duration and intensity of the 
activity. Therefore, assessment of physical activity can be diverse and difficult. Metabolic 
equivalent (MET) value measures energy expenditure and represents the intensity of a 
specific physical activity.
45,46
 More precisely, one MET (e.g. sitting quietly or lying down) 
represents the ratio of metabolic rate as a standard BMR of a healthy adult with a normal 
weight, which equals to an oxygen consumption of 3.5 ml O2 * kg
-1
 body weight * min
-1
 or an 
energy expenditure of 1 kcal * kg
-1
 body weight * hour
-1
. A higher MET-value means that the 
more intense the activity is, the more energy is expended during performance of the activity. 
For example, the energy expenditure of performing a physical activity with an intensity of 7 
MET (e.g. running) equals to 7 * 1 kcal * kg
-1
 body weight * hour
-1
. Thus, total energy 
expenditure for a specific physical activity can be calculated given an individual’s body 
weight and duration of the performed activity.
47
 
 
Associations between physical activity and PD 
An inverse association between physical activity and risk of PD was first reported by Sasco 
and colleagues in 1992.
48
 They reported a lower risk of PD for men who played sports in 
college and adulthood. However, no association between regular exercise or competitive 
sports and risk of PD was found in two later case-control studies.
49,50
 A recent population-
based case-control study, on the contrary, showed that individuals engaged in overall physical 
activity and leisure time competitive sports at high levels had lower risk of PD.
51
 
 
The few prospective cohort studies investigating the effect of physical activity on risk of PD 
have yielded inconsistent findings.
52-56
 Recreational physical activity (e.g. climbing stairs, 
walking or jogging) was not associated with PD in the Harvard Alumni Health Study.
52
 
However, moderate to vigorous level of recreational physical activity was associated with 
lower risk of PD in the Cancer Prevention Study II Nutrition cohort
53
 and NIH-AARP Diet 
and Health Study cohort.
55
 Similarly, higher levels of physical exercise was associated with 
lower risk of PD in the Health Professionals’ Follow-up Study and Nurses’ Health Study 
cohorts, although the association was only significant for men but not for women.
54
 Lastly, a 
recent study showed that heavier leisure-time physical activity was related to a stronger 
reduction of PD risk.
56
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Gender differences regarding the effect of physical activity on PD are plausible, but previous 
studies mainly assessed physical exercise in PD and did not consider possible differential 
effects between men and women. In addition, it is particularly important to study the effect of 
total physical activity (i.e. all activities together) instead of physical exercise on PD risk, as 
the total physical activity may be more realistically achievable for many. 
 
 
2.3.2.2 Tobacco 
Use of tobacco products, or more specifically, smoking of cigarettes, is one of the most 
studied lifestyle factors related to PD. An inverse association between cigarette smoking and 
PD was first observed more than 50 years ago, with a standardized morality ratio of 0.36 in 
regular cigarette smokers compared to non-smokers.
57
 Subsequently, more than 40 
retrospective case-control studies have been conducted to investigate the association between 
cigarette smoking and risk of PD. Their results were summarized in a meta-analysis, showing 
a pooled relative risk of PD of 0.59 (95% CI 0.55-0.65) for ever smokers, 0.88 (95% CI 0.75-
1.02) for past smokers, and 0.41 (95% CI 0.32-0.51) for current smokers, compared to never 
smokers.
58
  
 
However, the inverse association between smoking and PD has been criticized regarding 
potential biases related to the study design nature of case-control studies.
59,60
 These biases 
include recall bias, selection of inappropriate controls or selective mortality of smokers 
among PD-free individuals (selection bias), inaccurate recording of PD diagnoses in smokers 
(information bias), and that preclinical PD patients may be less prone to smoke or more likely 
to quit (reverse causation).
61
 Notably, results from prospective studies including nested case-
control
62-64
 and large cohort studies
61,65-69
 confirmed the strong inverse association between 
cigarette smoking and risk of PD, in which potential biases such as selective mortality have 
been addressed.
70
 More importantly, a dose-dependent risk reduction of PD was suggested, 
with more intense and longer duration of smoking related to reduced PD risk.
61,66,69,71
 
 
Among numerous chemicals responsible for the potential protective effect, nicotine is 
considered the most plausible candidate, primarily because it stimulates dopaminergic 
systems and provides a neuroprotective effect in experimental models of PD.
72,73
 
Accordingly, research on different tobacco products, in particular nicotine concentrated 
products without combustion of tobacco such as chewing tobacco or snuff, may better 
explore what constituent of tobacco smoke is responsible for the reduced risk of PD. Yet only 
 12 
two studies with small sample sizes are available, both of which have uncovered a strong 
inverse relationship between smokeless tobacco use and PD.
74,75
 
 
In Sweden, there is a long history of producing and using a wet snuff (i.e. an oral moist, 
finely ground and smokeless tobacco product), “snus” in Swedish (Figure 1.2).76 Production 
of snus once reached to 7000 tons (1.2 kilograms/capita) in 1919, but was almost diminished 
during the 1950s and 60s because of high prevalence of cigarette smoking among Swedish 
men.
77
 Nevertheless, snus use has increased since the mid-1970s as the prevalence of 
smokers has decreased, and in 2015 about 19% of men and 4% of women were daily snus 
users in Sweden.
78,79
 
 
 
Figure 1.2 Illustrations of snus sold in the market in Sweden (private picture from the author) 
 
 
The health consequences of using snus have not been studied in detail. Besides a few studies 
that have reported harmful effects of snus use on cardiovascular diseases and cancers,
80,81
 
most epidemiological evidence have shown that snus use does not lead to increased risk of 
cancers, cardiovascular diseases, or mortality.
82-85
 Many have considered snus an example of 
a “Swedish experience” that is perceived as a less harmful tobacco product compared to 
cigarettes,
86-89
 although the less harmful nature of snus use has been debated among both 
researchers and the general public.
90-94
 No one has investigated relationship between snus use 
and PD. 
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2.3.2.3 Antioxidants 
Oxidative stress has long been hypothesized to be involved in the pathogenesis of PD.
95,96
 
Experimental and clinical evidence showed that oxidative stress can induce mitochondria 
damage and modulate intracellular signaling,
97
 leading to production of cytotoxic free 
radicals and dopaminergic neuron death by necrosis and apoptosis.
98
 Therefore, antioxidants 
have been suggested as neuroprotective agents in PD based on their property of reducing 
oxidative damage, presumably by suppressing radical generation.
99-101
  
 
Conversely, evidence from experiments and observational studies on the relationship between 
antioxidant vitamins and PD is inconclusive.
102
 Among previous epidemiological studies 
conducted on dietary antioxidant vitamins and risk of PD, most have been case-control 
studies,
103-112
 while only a few studies were prospective.
63,67,113,114
 A lower risk of PD was 
found for higher total intake of vitamin E in the Singapore Chinese Health Study, but not for 
total intake of vitamin C or A.
67
 In the Health Professionals’ Follow-up Study and Nurses’ 
Health Study cohorts, no association was found between risk of PD and total intake of 
antioxidant vitamins, including vitamin C and E, and carotenoids.
114
 Interestingly, an inverse 
association between vitamin E intake and risk of PD was found when considering intake of 
vitamin E from foods only.
114
 Vitamin B6, B16, and folate were not related to PD in two 
cohort studies,
115
 but vitamin B6 was associated with a decreased risk of PD in the Rotterdam 
cohort study.
116
 Moreover, a recent large prospective study revealed an inverse association 
between vitamin C and PD risk.
117
 In summary, previous evidence suggests that vitamin E 
and possibly vitamin C and beta-carotene may lower the risk of PD.
118,119
  
 
Given the plausible neuroprotective effect of antioxidants on PD and that the major source of 
antioxidants is various food items, it is important to investigate the overall effect of dietary 
antioxidants in relation to PD risk. Total antioxidant capacity (TAC), a single measure of the 
free-radical-reducing capacity from all antioxidants present in foods, is probably the best 
measure in this context. 
 
TAC of diet can be estimated using an oxygen radical absorbance capacity (ORAC) assay 
[µmol Trolox equivalents per 100 g] that takes into account the synergistic effects of 
thousands of compounds in foods.
120-122
 The use of TAC has been assessed in relation to risk 
of myocardial infarction,
123
 cataract,
124
 and other medical conditions,
125-127
 but no one has 
investigated the relationship between TAC and risk of PD. 
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2.3.2.4 Socioeconomic status 
Socioeconomic status (SES) has been studied in relation to many health consequences, 
including both morbidity and mortality. Defining SES, however, is challenging. The main 
issue remains in the measurement of SES, which can be broadly covered by both social class 
and social indicators.
128
 These two aspects somehow define the SES as ‘socioeconomic 
position’, a combined measure of social status and economic situation. 
 
According to well-known sociologists, Karl Marx and Max Webber, the society can be 
stratified into different classes, where an occupational class or a group of people can share 
‘life-changes’ and own the means of production.128 Therefore, social class represents ‘social 
position (status)’ that indicates a particular structure location within society.129 Social 
indicators, such as educational level and income, are strongly related to social class 
(measured by occupation).
130
  Since occupation, education and income are closely correlated 
with each other, they are commonly used in epidemiological research and often 
interchangeable. However, these socioeconomic indicators possess unique qualities and each 
of them can influence people’s health and mortality accordingly.131 
 
SES is often considered as a measure of family income or highest education level in studies 
from North America,
132,133
 whereas SES is often characterized as individual occupational 
class in European studies.
134,135
  In Sweden, sociologist Robert Erikson and colleagues 
constructed the Swedish Socioeconomic Classification Index (SEI) in the 1970s, by 
classifying occupations into different social class categories.
136,137
 The SEI distinguishes 
between employers and employees (see appendix 1). According to the SEI, employees are 
divided into manual and non-manual workers, and classified further into high- and low-level 
sub-categories based on educational level required for the occupation.
137
  
 
Notably, the SEI classification is coded differently in the Swedish censuses from 1960 to 
1990. For example, SEI in the 1980 census has 17 different social and occupational classes, 
whereas in the 1990 census 12 classifications are available together with 3 additional 
categories that cannot be assigned to a social class (see appendix 2).
138
 The latter 3 categories 
are referred to as “unclassifiable employed”, “missing SEI information”, and “not in the labor 
force” such as students and pensioners.  
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Social epidemiology is the “study of relations between social factors and disease in 
populations”.139 A few studies have examined the association between SES and PD but most 
of them used a single social indicator such as education or occupation.
132,140
 Limited numbers 
of studies on a higher hierarchical measure of SES and PD are, in part, due to the difficulties 
of measuring SES and explaining the plausible mechanisms behind the observed association. 
However, it has been shown that SEI is a good indicator for the combined measure of SES 
and individuals above age of 30 years have a stable occupation during 20
th
 century in 
Sweden.
141-143
 Moreover, many Swedish studies have investigated associations between SES 
(classified according to SEI) and medical conditions, including neurodegenerative diseases.
144
 
 
Therefore, SES classified according to the SEI, can be of interest in epidemiological research 
both for descriptive purposes and for formulating new hypotheses about the role of 
environmental and social factors in PD etiology. Such research may also help develop 
equitable healthcare service available to PD patients. 
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3 AIMS 
The overall aim of this thesis is to understand better the relationship between several lifestyle 
factors and subsequent risk of PD. 
 
In particular, in different studies, we aim: 
 
Study I: to study whether physical activity is associated with risk of PD; 
 
Study II: to examine the association between smokeless tobacco (Snus) use and risk of PD; 
 
Study III: to investigate the effect of dietary antioxidants on PD risk; and 
 
Study IV: to explore the association between SES and PD risk, as well as the effect of SES 
on all-cause mortality in PD patients and PD-free individuals. 
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4 MATERIAL AND METHODS 
4.1 Swedish Population Registers 
Sweden has more than 300 years of history on population statistics that originated from 
parish registrars. Later in the 19
th
 century, Statistics Sweden (Swedish: Statistiska 
Centralbyrån) and National Board of Health and Welfare (Swedish: Socialstyrelsen) were 
established as governmental agencies for the purposes of registering population statistics and 
health records.
145,146
 
 
In 1947, personal identification number (PIN) was introduced to the Swedish society and has 
become a crucial part of Swedish healthcare administration since then. The PIN is assigned to 
every person who is born in Sweden, as well as to immigrants who intend to stay in Sweden 
for more than one year. This number is unique to everyone and enables record linkage with 
all administrative and health registers in Sweden.
147
  
 
 
4.1.1 National Patient Register 
The national patient register (NPR) started in 1964 and became nationwide in 1987. The NPR 
covers all hospital discharge diagnoses in Sweden.
148
 Since 2001, the NPR also includes 
outpatient specialist visits at clinics. Diagnoses given in primary healthcare settings are not 
covered by the NPR. Diagnoses in the NPR are coded by the Swedish revisions of the 
International Classification of Diseases (ICD). In addition, dates of diagnosis, admission to, 
and discharge from hospital are also recorded in the NPR. The NPR is managed by the 
National Board of Health and Welfare.  
 
 
4.1.2 Cause of Death Register 
In Sweden, death records dates back to the 18
th
 century. This system gradually formed the 
cause of death register (CDR) and reached nationwide coverage in 1961. The CDR was 
managed by Statistics Sweden in the early 20
th
 century but migrated to the National Board of 
Health and Welfare in 1994.
149
 The CDR contains data on date of death as well as main and 
secondary diagnoses of death for all individuals registered in Sweden, regardless of whether 
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the death occurs inside or outside the country. Causes of death in the CDR are also coded 
according to the Swedish revisions of the ICD. 
 
 
4.1.3 Swedish Twin Registry 
The Swedish Twin Registry (STR) contains more than 170,000 twins born in Sweden from 
1886 and onwards.
150,151
 In addition to the PIN that everyone has in the Swedish 
administrative registers, twins in the STR have a unique twin identification number enabling 
record linkage with all sub-cohorts of the register. Zygosity information on same-sexed twins 
are assessed by questions in the questionnaires and easily identified through twin 
identification number. The questions used for determining zygosity have been validated with 
an accuracy of 99% compared with genotyping.
152
 
Figure 4.1 Swedish register data and cohort data used in this thesis 
1. SNMC = Swedish National March Cohort; 2. CWC = Construction Workers Cohort; 3. MONICA = 
Multinational Monitoring of Trends and Determinants in Cardiovascular Disease; 4. VIP = Västerbotten 
Intervention Program; 5. WOLF = Work, Lipids and Fibrinogen Study; 6. SALT, Screening Across the Lifespan 
Twin Study; 7. SPHC = Stockholm Public Health Cohort; 8. SMC = Swedish Mammography Cohort; 9. COSM 
= Cohort of Swedish Men; 10. Census data; PIN = Personal Identification Number 
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4.2 Types of Study Design 
4.2.1 Swedish National March Cohort (Study I) 
4.2.1.1 Study participants 
The Swedish National March Cohort (SNMC) was assembled during a 4-day promotional 
and fund-raising event for the Swedish Cancer Society in almost 3600 cities and villages in 
Sweden in September 1997. During the event, all participants were invited to fill out a 36-
page questionnaire with background data on lifestyle and medical history.  
 
The SNMC is a general population cohort, in which participants provided their PIN, enabling 
identification of health status and possible follow-up monitoring through record linkage to all 
nationwide administrative registers in Sweden.
153
 
 
Due to the specific characteristic of this event, the total number of participants who received a 
questionnaire was unknown. In total 43,880 participants completed the questionnaire in the 
SNMC. After exclusion of incorrect PIN, 43,852 participants were included in the cohort. We 
further excluded participants who had a record of PD diagnosis (n=10), death (n=8), or 
emigrated out of Sweden (n=466) before start of follow-up. Therefore, the final sample used 
in study I included 43,368 participants, consisting of 15,505 (35.7%) men and 27,863 
(64.3%) women. Study participants were followed from baseline on October 1, 1997 until 
date of PD, death, emigration, or end of follow-up on December 31, 2010, whichever came 
first (Figure 4.2). 
 
 
4.2.1.2 Assessment of physical activity 
To investigate the association between physical activity and risk of PD, we analyzed most 
types of physical activity assessed in the questionnaire of SNMC in study I. These activities 
include household and commuting activity, leisure time exercise, occupational activity, and 
total daily physical activity.  
 
Regarding household and commuting physical activity, participants reported how many hours 
per week (i.e. < 1, 1-2, 3-4, 5-6, or > 6 hours), on average, they spent on these activities such 
as cleaning the house, working in the garden, or walking/biking to work.  
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Figure 4.2 Flowchart describing the analytical sample of the Swedish National March Cohort 
 
 
Regarding occupational physical activity, participants reported how physically demanding 
their daily job was during the last year (i.e. mostly sedentary, light but moving a little, rather 
strenuous, and very strenuous). 
 
Regarding leisure time exercise, participants reported how many hours per week (i.e. never, 
0-1, 2, 3, 4, or ≥ 5 hours), on average, they spent on exercise or outdoor activities. Leisure 
time exercise was assessed at three levels: light (e.g. casual walking), moderate (e.g. speedy 
walking, jogging or swimming), and heavy (e.g. vigorous training or competitive sporting) 
and was measured separately in summer and winter. 
 
With regard to total daily physical activity, we assessed the activity level represented for a 
typical 24-hour day using a validated instrument (the Energy Expenditure Questionnaire, 
EEQ) with nine fixed scale steps.
154
 Each scale step was exemplified by common activities. 
The nine scale steps together represented different estimates of activity in terms of MET-
value, and were obtained from questions that were typically asked in epidemiological 
research. To calculate total physical activity level, hours engaged in each scale step were 
summed using  
∑ 𝑡𝑖 × 𝑀𝐸𝑇𝑖
9
𝑖=1               (1) 
As a result, mean intensity of total physical activity in a 24-hour day could be estimated for 
all activities in MET hours per day (MET-hours/day). Assessments for other physical 
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activities in the SNMC such as sedentary behavior have been described in detail previously 
but were not studied in the present study.
153
  
 
Variables of physical activity were further processed before statistical analyses in study I. 
First, numbers of hours spent on household and commuting activity and leisure time exercise 
were quantified into MET-hours/day. The conversion was based on estimated oxygen 
consumption associated with these activities (e.g. 4.0 MET for household and commuting 
activity; 3.0, 6.0 and 10.0 METs for light, moderate and heavy leisure time exercise). In 
addition, we combined household and commuting activity and leisure time exercise into a 
variable termed “general physical activity”. Scores of MET-hours/day of physical activity 
were then categorized into tertiles with separate cut-offs for all participants, men and women.  
 
 
4.2.2 Swedish Collaboration on Health Effect of Snus Use (Study II) 
4.2.2.1 Study participants 
The Swedish Collaboration on Health Effects of Snus Use is a national consortium aimed to 
study the effect of snus use on human health. The collaboration pools almost all prospective 
cohort studies with information on the use of Swedish snus and tobacco smoking in the 
country. Study designs and measures for individual cohorts included in the collaboration were 
described in detail elsewhere.
81,85,150,153,155-158
 At present, eight prospective cohort studies are 
included in the snus collaboration, of which individual participant data from seven cohorts 
were collected for study II. 
 
Among individuals in the seven cohorts, only men (n=351,640) were included in study II 
due to extremely low prevalence of snus use in women at the time of study enrolment (Table 
4.1). In addition, participants were excluded from analyses if they had a record of PD 
diagnosis (n=148) or if they were younger than 18 years (n=2891) before baseline, resulting 
in 348,601 participants. All participants in each cohort were followed from baseline until date 
of first-ever PD diagnosis, death, or end of follow-up, whichever came first. 
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Table 4.1 Cohorts included in the SNUS collaboration (men only) 
 Number of 
participants 
(n) 
Incident 
PD cases 
(n) 
Never-tobacco 
smoker  
(%) 
Ever-snus 
user 
(%) 
Age at 
recruitment 
(mean±SD) 
Follow-up 
period 
(mean±SD) 
CWC 214,381 474 45.8 29.8 34.2±12.5 20.0±5.1 
SPHC 39,212 89 55.3 27.8 50.2±16.9 4.8±3.1 
MONICA 4,553 31 43.4 38.6 49.0±13.4 12.5±6.3 
SNMC 15,012 165 50.2 23.1 53.4±17.1 12.6±2.5 
SALT 18,316 117 45.5 23.9 56.6±8.0 10.0±1.6 
VIP 49,940 291 48.2 42.2 47.2±9.2 12.4±6.3 
WOLF 7,187 32 49.3 34.3 42.9±10.8 13.9±2.1 
Scania 6,198 20 46.6 N/A 48.6±16.7 9.0±0.4 
 
Scania was excluded from the study II because information on snus use status was only available for current or 
non-current snus use. SD = Standard deviation; PD = Parkinson’s disease; CWC = Construction Workers 
Cohort; SPHC = Stockholm Public Health Cohort; MONICA = Multinational Monitoring of Trends and 
Determinants in Cardiovascular Disease; SNMC = Swedish National March Cohort; SALT = Screening Across 
the Lifespan Twin Study; VIP = Västerbotten Intervention Program; WOLF = Work, Lipids and Fibrinogen 
Study; Scania = Scania Public Health Cohort.  
 
 
4.2.2.2 SALT and Q-73 
In addition to twins from the Screening Across the Lifespan Twin Study (SALT) included in 
the snus collaboration, a nested case-control study design was further employed within study 
II, including additional twins born 1926-1958 who participated in a questionnaire sent in 
1972-1973 (Q-73 cohort).
152,159
 Purposes of this nested case-control study were to examine: 
1) whether possible misclassifications or changes of exposure during the follow-up attenuated 
the association, and 2) whether there was a dose-response relationship between years of 
lifetime snus use and risk of PD. 
 
 
4.2.2.3 Assessment of snus use 
Snus use was assessed at baseline through a questionnaire in six cohorts and structured 
telephone interview in one cohort in study II. Information on tobacco smoking during 
lifetime was also collected. In addition, participants who were current users of snus at 
baseline provided their average amount (cans per week) and duration (years) for the snus use.  
 
To investigate the effect of snus use on PD risk in study II, all participants in the seven 
cohorts were classified as “never user”, “former user”, or “current user” for their lifetime 
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regular use of snus and for any type of smoked tobacco products (e.g. cigarettes, pipes and 
cigars). In addition, amount of snus use for those who were current users at baseline was 
categorized as “light” (i.e. less than 2 cans per week) or “moderate-heavy” level (i.e. equal to 
or more than 2 cans per week), except for SNMC in which the “light level” equals to “less 
than or equal to 2 cans per week”. Regarding duration of snus use for current users at 
baseline, we categorized the duration into “1-20 years” or “more than 20 years”. Further, to 
examine the combined effect of snus use and tobacco smoking on future risk of PD, 
participants were cross-classified into different groups based on their answers on both snus 
use and tobacco smoking at baseline. Subsequently, those who “never used snus and never 
smoked tobacco products” were treated as the reference group.  
 
 
4.2.3 Swedish Mammography Cohort and Cohort of Swedish Men (Study III) 
4.2.3.1 Study participants 
The Swedish Mammography Cohort (SMC) was first assembled in 1987 for the purposes of 
investigating the relationship of dietary and hormonal factors with risk of breast cancer. All 
women born 1914-1948 and living in Västmanland and Uppsala counties in central Sweden 
were invited to participate in the study. In 1997, those who were still alive and living in the 
area were contacted again to fill-out a 350-item questionnaire with detailed information on 
lifestyle and other risk factors for non-communicable diseases (70% response rate). In total 
38,984 women were eligible for study III. 
 
The Cohort of Swedish Men (COSM) was assembled in 1997. All men born 1918-1952 and 
living in Västmanland and Örebro counties in central Sweden were invited to answer a 
questionnaire identical to the one used in SMC, except for some sex-specific questions (49% 
response rate). In total 45,906 men were eligible for study III.  
 
Participants in the SMC and COSM were excluded from analyses if they had a record of PD 
diagnosis in the NPR at study enrollment (n=116), resulting in 38,937 women and 45,837 
men included in the study III. They were followed from baseline (September 15, 1997 for 
SMC and January 1, 1998 for COSM) until date of first-ever PD diagnosis, death, or end of 
follow-up on December 31, 2014, whichever came first. 
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4.2.3.2 Assessment of Dietary antioxidants 
The questionnaires sent to participants in the SMC and COSM in 1997 contained a 96-item 
food-frequency questionnaire (FFQ) tailored to the Swedish diet. The FFQ assessed 
participants’ dietary habits including exact consumption for each type of food component 
(per day or per week) during the past year. 
 
To investigate associations between dietary antioxidants and risk of PD, intake of dietary 
antioxidants (including vitamins C and E, and beta-carotene) was calculated using food 
composition values from the Swedish Food Administration Database.
160
. An example of the 
calculation is illustrated below 
Vitamin Cfood item-1 = mean frenquency × Vit C content in the database     (2) 
Vitamin Ctotal = ∑ Vitamin Cfood item−n
n
i=1                                                         (3) 
in which the intake of vitamin C is in unit of mg/day and values used for nutrient content for 
each food item are age- and sex-specific portion size. Similarly, dietary TAC was calculated 
using a formula  
TAC = ∑ ORACfood item−n
𝑛
𝑖=1                (4) 
 
Several validation studies of the FFQ used in study III have been performed previously. 
Self-reported micronutrient estimates were compared against 24-h recall interviews, showing 
a mean correlation coefficient of 0.62.
161,162
 A moderate correlation (0.31) between self-
reported TAC and plasma ORAC values was reported in another validation study.
163
 
 
 
4.2.4 Swedish Census (Study IV) 
4.2.4.1 Study participants 
Statistics Sweden was responsible for population and housing censuses in Sweden between 
1960 and 1990. In each decade, census questionnaires were sent to all Swedish residents who 
were older than 16 years old at the time of the census. Since it was mandatory to answer the 
census questionnaire, the response rate was extremely high at >99%.
164
 In the census 
questionnaire, detailed information on demographic statistics were collected, including but 
not limited to housing, marital status, highest level of education, occupation, and social class. 
Individuals participated in the 1980 census were primary included in study IV 
(n=8,318,187). Data from the census questionnaires sent in 1960 and 1970 were also 
extracted. 
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Participants younger than 30 years of age at the time of the 1980 census were excluded 
(n=3,301,474), since previous studies reported a stable occupation and social class for 
individuals who were older than 30 years old.
141-143
 Individuals with incorrect or missing 
Swedish registration number, date of death or migration, and SES information were also 
excluded (n=818). In addition, participants who had a record of PD diagnosis, death, and 
migration before start of follow-up on January 1, 1981 were excluded, resulting in 4,630,828 
(48.5% for men and 51.5% for women) in study IV. 
 
To study the association between SES and risk of PD, all participants were followed from 
baseline until date of PD diagnosis, emigration, death, or end of follow-up on December 31, 
2010, whichever came first. 
 
To study the association between SES and all-cause mortality while accounting for PD status, 
all participants were followed from baseline until date of death, emigration, or end of follow-
up on December 31, 2010, whichever came first. The PD diagnosis was treated as a time-
varying covariate that separates an individual’s follow-up time into a PD-free period and a 
PD period. 
 
 
4.2.4.2 Assessment of socioeconomic status 
In the census questionnaires, questions about occupational history were asked. All 
participants in the 1980 census were categorized into 8 SES groups based on their answers 
identified with SEI (Table 4.2). The first four groups are considered ordered from the highest 
to the lowest SES, whereas the remaining groups may not be ordered. 
 
A large group of individuals (i.e. group 7 and 8, n=1,173,184) had unclear SES in the 1980 
census, of whom pensioners accounted 85% of the group. SES information for these persons 
was therefore collected from census questionnaires sent in 1970 or in 1960, wherever 
available. 
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Table 4.2 Classification of SES according to SEI in study IV 
 Socioeconomic groups N SEI Examples 
1 Higher non-manual workers 862,724 46, 56  
2 Lower non-manual workers 557,817 33, 36  
3 Higher manual workers 575,829 21, 22  
4 Lower manual workers 1,294,068 11, 12  
5 Self-employed workers  273,965 60, 79 Company or farm owners 
6 Farmers   187,690 89  
7 Pensioners 547,811 95  
8 Unclassifiable employed 
workers 
330,924 91, 96, 97, 
98, 99 
House-workers and employed 
individuals that could not be assigned 
to an occupational class 
 
SEI codes are not consecutive. N = number of participants included in the in study IV. 
 
 
 
4.3 Outcome Ascertainment 
Risk of PD was the primary outcome in studies I - IV. Incident PD cases were defined as 
individuals with a first-ever PD diagnosis in the NPR or the CDR, except for study II, in 
which PD cases were only identified from the NPR. The ICD codes used for PD were: 350 
(ICD-7, 1964-68), 342 (ICD-8, 1969-86), 332.0 (ICD-9, 1987-96), and G20 (ICD-10, 1997-
current). Date of first-ever PD diagnosis was defined as date of first hospital admission or 
outpatient contact, or date of death for cases only identified from the CDR. All-cause 
mortality was another outcome in study IV and it was defined as any death record in the 
CDR. 
 
PD diagnoses in the NPR and the CDR have been validated against clinical diagnoses and 
showed a positive predictive value of 70.8% for the NPR and 66.7% for the CDR.
165
 The 
sensitivity for PD diagnosis is 72.7% in NPR and 83.1% for the two registers combined. 
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4.4 Assessment of Covariates 
Several covariates were considered as possible confounders based on subject knowledge, 
literature review, and causal diagrams known as directed acyclic graphs (DAG). Relevant 
information on those covariates was collected based on the availability in each study. Briefly, 
these covariates include cigarette smoking (study I - IV), alcohol intake (study I - III), 
coffee intake (study I - III), BMI (study I, III), educational level (study I - III), physical 
activity level (study II), total energy intake (study III), marital status (study IV), and area of 
living (study IV). 
 
 
4.5 Statistical Methods 
4.5.1 Cox Proportional Hazards Regression (Study I - IV) 
Cox proportional hazards regression model with attained age as the underlying timescale was 
used as the primary statistical method (i.e. age-adjusted model) to estimate HRs with 95% 
CIs in all studies (study I - IV). Analyses were conducted for all participants (i.e. two 
genders combined) in study I and IV and stratified by gender in study I - IV. In addition to 
the age-adjusted model, we used a multivariable-adjusted model that adjusts for other 
possible confounders in each study.  
 
In the multivariable-adjusted model for analyzing physical activity in study I, sex, cigarette 
smoking, alcohol and coffee intake, BMI, and educational level were included. In the 
analyses of snus use in study II, to avoid potential confounding effect from tobacco smoking 
on the association between snus use and PD risk, primary analyses were restricted to never 
smokers. Other covariates included in the multivariable-adjusted model were alcohol, 
education and physical activity in Stockholm Public Health Cohort; alcohol and physical 
activity in Multinational Monitoring of Trends and Determinants in Cardiovascular Disease 
Cohort; alcohol and physical activity in SNMC; alcohol, education, physical activity and 
coffee intake in SALT; education, alcohol and coffee intake in Västerbotten Intervention 
Program; alcohol, education and physical activity in Work, Lipids and Fibrinogen Study. 
Multivariable-adjusted model used in study III for analyses of dietary antioxidants was 
similar to the one used in study I, with additional adjustment for total energy intake. In study 
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IV, sex, marital status, and area of living were adjusted for in the multivariable-adjusted 
model.  
 
Continuous exposures (e.g. MET-hours/day for physical activity in study I and mg/day for 
vitamin C intake in study III) were analyzed as both continuous and categorical variables, 
whenever possible. Trend analyses were performed for categorical variables, using the 
median of each exposure category as a single ordinal variable in the modelling (study I - III). 
The lowest category was used as the reference group in all analyses for categorical variables, 
except for study IV where participants with the highest SES (i.e. higher non-manual 
workers) was the reference group. Furthermore, possible effect modifiers (e.g. gender, age 
group, or PD status) on the association between exposures and PD risk were examined in 
study I and IV. 
 
Proportional hazards assumption in the Cox model was examined in all studies, using scaled 
Schoenfeld residuals by plotting them against a function of the timescale and testing for 
linear trend.
166
  
 
 
4.5.2 Meta-analysis (Study I & II) 
To calculate the summarized effect of physical activity (study I) and snus use (study II) on 
the risk of PD, estimates of HRs and 95% CIs from each individual study or cohort were 
pooled using meta-analyses with a random-effects model.
167,168
 Heterogeneity among studies 
included in the meta-analyses was examined using Q test and I
2
 statistics.
169
  
 
 
4.5.3 Conditional Logistic Regression (Study II) 
Lifetime duration of snus use was calculated in years for all male twins nested in the Q-73 
and SALT cohorts. PD cases were matched to five controls by age. A conditional logistic 
regression model was used to compare lifetime duration (years) of snus use in cases and 
controls. 
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4.5.4 Sensitivity analyses (Study I - IV) 
A rich set of sensitivity analyses was performed for different purposes in each study. These 
analyses are introduced briefly below. Firstly, to exclude the possibility of reverse causality 
such that pre-clinical PD influences the exposures, lag-time analyses were conducted in study 
I – III. In study I & II, the first 8 years of follow-up were excluded, and in study III, the 
first 4 years were excluded. Secondly, to avoid potential confounding from tobacco smoking 
on the observed associations, analyses restricted to never smokers were performed in study II 
& III. Thirdly, the influence of primary or secondary PD diagnoses from the registers was 
also investigated by restricting the analyses to primary PD diagnosis as the definition of 
outcome (study I). Fourthly, multiple imputation was applied to assess the impact of missing 
values of covariates on the estimates of observed associations (study I & II). Further, to 
examine the effect of the cohort with most weight on the pooled estimates in the meta-
analyses, the Construction Workers Cohort was excluded in study II. Finally, the effect of 
health seeking behavior on the association between SES and PD risk was examined in study 
IV.  
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5 MAIN RESULTS 
5.1 Physical Activity and Parkinson’s Disease (study I)  
There was an inverse association between time spent on household and commuting activity 
and risk of PD. For example, there was an up to 43% risk reduction observed for participants 
who spent more than 6 hours on such activities (Table 5.1). A lower risk of PD was also 
found for participants with higher physically demanding levels of occupational activity, 
though this was not statistically significant. 
 
 
Table 5.1 Risk of Parkinson’s disease according to household and commuting activity and 
occupational activity for all participants in the Swedish National March Cohort 
   n HR 95% CI P-trend 
Household and commuting activity     
 <2 h/week  46 1 Reference  
 3-4 h/week  78 0.68 0.46-1.00  
 5-6 h/week  67 0.70 0.47-1.04  
 >6 h/week  95 0.57 0.39-0.83  
      0.01 
Physical demanding level of occupational activity     
 Mostly sedentary  31 1 Reference  
 Moving a little   209 0.91 0.60-1.38  
 Strenuous  40 0.74 0.46-1.22  
      0.20 
 
n = number of Parkinson’s disease cases; HR = hazard ratio; CI = confidence interval. 
 
 
 
When physical activities were analyzed in terms of MET-hours/day, there was no association 
between leisure time exercise and risk of PD (Figure 5.1). However, general physical activity 
(i.e. leisure time exercise and household and commuting activity combined) was associated 
with a lower risk of PD in men and in the full sample with both men and women. Notably, a 
45% lower risk of PD (HR 0.55, 95% CI 0.35-0.87) was found for men with a medium level 
of total physical activity (mean = 39.1 MET-hours/day) compared to men with a low level of 
total physical activity (mean = 30.3 MET-hours/day).  
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Figure 5.1 Associations between physical activity (MET-hours/day) and risk of Parkinson’s disease 
Physical activity was measured in MET-hours/day and categorized into tertiles. HR = hazard ratio. 
 
 
We did not find an interaction effect with gender for any of the physical activity exposures 
mentioned above (P for interaction = 0.62, 0.62, 0.50, 0.15, 0.20 for household and 
commuting  activity, occupational activity, leisure time exercise, general physical activity, 
and total physical activity, respectively).  
 
When we pooled all previous cohort studies on physical activity in relation to risk of PD, four 
studies were included in the analyses stratified by gender.
52-55
 We found that higher levels of 
physical activity were associated with lower risk of PD in both men and women (Figure 5.2).  
 
Lastly, all sensitivity analyses showed similar results compared to the main analyses. For 
example, when only primary diagnosis of PD was used to define PD cases, multivariable-
adjusted HR for the medium level of total physical activity was 0.52 (95% CI 0.31-0.90). 
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Figure 5.2 Forest plot - Pooled estimates of physical activity for risk of Parkinson’s disease from all 
previous cohort studies (Reprinted from Yang F et al.,
170
 with permission from Oxford University 
Press) 
HRs were pooled using meta-analysis with a random-effects model. The size of each square is proportional to 
the weight of that study in the meta-analysis. HR = hazard ratio; CI = confidence interval. 
 
 
 
5.2 Snus and Parkinson’s Disease (Study II)   
There was an inverse association between snus use and risk of PD in the entire study 
population (Figure 5.3). When analyses were restricted to never-tobacco smokers, men who 
ever used snus had a substantially lower risk of PD compared to never-snus users. The 
inverse association between snus use and PD risk was even greater for current-snus users, 
whereas an inverse but non-significant association between former-snus users and PD risk 
was observed (Table 5.2). 
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Figure 5.3 Forest plot - Pooled HR of snus use for risk of Parkinson’s disease in seven Swedish 
prospective cohort studies 
The size of each square is proportional to the weight of that study in the meta-analysis. Number of cases is for 
the exposed group (i.e. ever-snus users). Reference group is never-snus users. HR = hazard ratio, CI = 
confidence interval. 
 
 
Table 5.2 Pooled HR of snus use for risk of Parkinson’s disease in seven Swedish prospective 
cohort studies among never-tobacco smokers 
   
n HR 95% CI 
Heterogeneity 
 I
2
 P-value 
Never-snus users 531 1 Reference   
Ever-snus users  27 0.41 0.28 – 0.61 0% 0.93 
Former-snus users  10 0.68 0.36 - 1.28 0% 0.91 
Current-snus users  17 0.38 0.23 - 0.63 0% 0.73 
n = number of cases; HR = hazard ratio; CI = confidence interval. 
 
 
In addition, non-smoking men with higher snus consumption and longer period of snus use 
had lower risk of PD (Figure 5.4 & 5.5). Moreover, when analyzing snus use and tobacco 
smoking together, more prominent risk reductions were found with current use regardless of 
tobacco type (Figure 5.6). Furthermore, results from several sensitivity analyses were 
comparable to that in the main analyses.  
 34 
 
Figure 5.4 Forest plot - Pooled HR of amount of snus use for risk of Parkinson’s disease  
The size of each square is proportional to the weight of that study in the meta-analysis. Analyses were conducted 
among current-snus users. Reference group is never-snus users. Number of cases is for the exposed group. HR = 
hazard ratio, CI = confidence interval. 
 
 
Figure 5.5 Forest plot - Pooled HR of duration of snus use for risk of Parkinson’s disease 
The size of each square is proportional to the weight of that study in the meta-analysis. Analyses were conducted 
among current-snus users. Reference group is never-snus users. Number of cases is for the exposed group. HR = 
hazard ratio, CI = confidence interval. 
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Figure 5.6 Combined effect of snus use and tobacco smoking on risk of Parkinson’s disease 
(Reprinted from Yang F et al.,
171
 with permission from Oxford University Press) 
HR = hazard ratio, CI = confidence interval. 
 
 
 
Lastly, when using SALT and Q-73 data and considering snus use, smoking, and alcohol 
drinking as time-varying exposures, PD cases had shorter duration of lifetime snus use than 
that in the controls (Table 5.3). 
 
 
Table 5.3 Association between years of lifetime snus use and Parkinson's disease risk 
 
Never-smokers 
n OR 95% CI P-value 
Per year of life-time snus use 115 0.96 0.93-1.00 0.04 
 
Analyses were performed using conditional logistic regressions with cases and matched controls (n=5) by age, 
adjusting for smoking (never, former, and current users), alcohol intake, educational level, and birth cohort. n = 
number of Parkinson's disease cases; OR = odds ratio; CI = confidence interval. 
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5.3 Diet and Parkinson’s Disease (Study III)   
In the multivariable-adjusted model, we found a lower risk of PD with higher intake of 
dietary β-carotene in both genders, and with higher intake of vitamin E in women (Figure 
5.7). Results remained significant in the 4-years lag-time analyses. In addition, the association 
of PD risk with higher intake of dietary vitamin C for women was borderline significant (HR 
0.91, 95% CI 0.83-1.00 for an increase per 50 mg/day; P-trend for categorical analysis = 
0.04). However, the inverse association for vitamin C intake in women was no longer 
significant in the 4-years lag-time analyses. There was no association between dietary TAC 
and PD risk. 
 
When analyses were conducted among never smokers, there was an inverse association 
between intake of dietary vitamin E and risk of PD in women (HR 0.65, 95% CI 0.46-0.90 
for highest quartile vs. lowest quartile; P-trend = 0.02). No other associations were observed.  
Figure 5.7 Associations between daily intake of dietary antioxidants and risk of Parkinson’s disease 
Intake of antioxidant vitamins was measured in mg/day. TAC was measured in micromole Trolox equivalents. 
All measures were categorized into quartiles with the lowest category as the reference group. HR = hazard ratio, 
TAC = total antioxidant capacity. 
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5.4 Socioeconomic Status and Parkinson’s Disease (Study IV) 
In general, individuals with lower SES were associated with lower risk of PD, but no clear 
dose-response relationship was found (Table 5.4). The associations were similar for all 
participants and for men and women separately. In addition, an analysis adjusting for hospital 
visits as a proxy of health seeking behavior did not change the association. Age group was an 
effect modifier for the association between SES and PD risk (P-value for interaction < 0.05), 
with weaker associations for low non-manual and high manual works in older ages. 
 
 
Table 5.4 Associations between socioeconomic status and risk of Parkinson’s disease for all 
participants 
   n HR 95% CI 
Socioeconomic status    
High non-manual workers  12,435 1 Reference 
Low non-manual workers  7,121 0.92 0.90 - 0.95 
High manual workers  8,224 0.88 0.86 - 0.91 
Low manual workers  18,537 0.93 0.91 - 0.95 
Self-employed workers  4,311 0.96 0.93 - 0.99 
Farmers  3,825 1.01 0.97 - 1.05 
Pensioners  8,575 1.08 1.05 - 1.11 
Unclassifiable  3,304 0.90 0.86 - 0.94 
 
n = number of incident Parkinson’s disease cases; HR = hazard ratio; CI = confidence interval. 
 
 
 
When all-cause mortality was considered as the outcome, standardized mortality rate was on 
average 3-fold higher in PD patients compared to PD-free individuals. Importantly, there was 
an inverse association between SES and all-cause mortality for both PD-free individuals and 
PD patients (Figure 5.8). In addition, we found that PD diagnosis was an effect modifier for 
the association between SES and all-cause mortality (P-value for interaction < 0.01), with a 
somewhat attenuated inverse association among PD patients. The associations were similar 
for all participants and for men and women separately. 
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Figure 5.8 Associations between SES and all-cause mortality in PD-free individuals and patients 
with PD. 
High non-manual workers were the reference group in this figure. SES = socioeconomic status, PD = 
Parkinson’s disease, HR = hazard ratio, CI = confidence interval.   
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6 DISCUSSION AND METHODOLOGICAL 
CONSIDERATIONS 
6.1 Association or Causation? 
It is crucial to distinguish between the concepts of association and causation. Although results 
on lifestyle factors and risk of PD from this thesis are compelling, it is not possible to 
conclude that these lifestyle factors truly prevent against the disease. Rather, it has to be 
acknowledged that an association does not mean a causal relationship. However, several 
arguments should be highlighted, which have been used to counteract the concerns arising 
when implying a causal effect from observational results.  
 
 
6.1.1 Study design 
In epidemiology, a cohort study is when “all subjects in a source population are classified 
according to their exposure status and followed over time to ascertain disease incidence”.139 
Under such a design with prospective data collection, exposures are measured at baseline 
(also known as the start of study) and during the follow up, an outcome (i.e. a disease) occurs 
later. Then, we can estimate the causal effect of the exposure on the outcome in some form, 
such as the ratio of the risk of the outcome in the exposed group compared to the risk among 
the unexposed group. Therefore, such an observed exposure-outcome relationship by nature 
implies causal inference, meaning that the exposure causes the outcome. In a retrospective 
cohort design, the study is initiated after the follow-up time has already passed and historical 
data are used. Nevertheless, if the exposure information was collected before the start of the 
study, the data collection is still considered prospective.  
 
A randomized controlled trial (RCT) is a type of prospective cohort study in which the 
exposure (i.e. experiment or intervention) has been randomly assigned within the cohort. 
RCTs have been considered the “gold standard” in making causal inference in clinical 
research, but they may face unethical, unaffordable or unfeasible issues to apply the treatment 
or intervention on human subjects. Observational (also known as nonexperimental) studies, 
on the other hand, have several advantages in investigating exposure-outcome relationships, 
such as ethical acceptability, cost efficiency and real-life applicability.
172
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Compared with cross-sectional and retrospective case-control studies which are unable to 
conclude causality or prone to reverse-causality, an observational prospective cohort study is 
probably better at mimicking an RCT for testing a causal hypothesis. Other advantages of a 
prospective design include the possibilities to study a rare exposure or multiple outcomes, 
assess the time between exposure and outcome, and estimate prevalence, incidence and 
relative risks. Conducting a prospective cohort study, however, is typically very expensive 
and may need a long follow-up time for certain diseases to be developed. Another important 
issue that should be considered is the potential large proportion of drop-out during the long 
follow-up period. 
 
In the present thesis, all studies (study I-IV) were conducted using a prospective cohort study 
design. As a result, all the exposure information were collected at the beginning of follow up 
and the first occurrence of PD diagnosis (study I-IV) or all-cause mortality (study IV) was 
the outcome. Therefore, potential problems arising from retrospective study designs such as 
recall bias were avoided. In addition, a nested case-control design was used in study II. A 
typical case-control study has advantages in studying rare diseases or diseases with a long 
latency period. It also allows studying multiple exposures in a single study. A nested case-
control design is simply a case-control study nested in a cohort with a dynamic sampling 
method. Compared with the classical case-control design, the nested case-control design 
provides further opportunities to study time-varying exposures or outcomes, or in a twin or 
sibling design to adjust for unmeasured familial confounding. Furthermore, estimates of odds 
ratios from the nested case-control design may be closer to the HRs estimated from the cohort 
design.
173
 
 
 
6.1.2 Prevalent cases versus incident cases 
Dopaminergic neuron degeneration is gradual. A PD patient is diagnosed based on cardinal 
signs of movement dysfunctions but by that moment, at least 80% of neurons are already lost. 
Many symptoms have been proposed as prodromal symptoms of PD (i.e. symptoms are 
present but not sufficient to diagnose the disease), yet the exact onset of PD is largely 
uncertain.
174
 In an epidemiological study, once the disease has developed, systematic 
measurement error of exposure will occur (i.e. differential misclassification) and the disease 
may alter the exposure (i.e. reverse causation), leading to biased results. Therefore, for the 
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purpose of risk factor identification, it is of utmost importance, to exclude prevalent cases at 
the beginning of follow-up and to study the effect of exposure on incident cases only. 
 
For the studies presented in this thesis, information on diagnosis of PD was collected from 
population-based registers, in which the date of first inpatient admission and/or outpatient 
contact was defined as the index date of diagnosis for an incident PD case. The index date is 
probably the closest one to the date of disease onset when such information is not available. 
However, a previous study reported an average time period of 7.5 years between clinical 
onset and register record of PD diagnosis in the NPR.
165
 Given this information, we 
performed lag-time analyses by excluding the first few years of follow up in studies I - III, 
and the conclusions remained. Regarding the possible long preclinical period (i.e. in which 
neurodegenerative processes start but no evident symptoms or signs are present), it was not 
possible to examine this issue since the data on prodromal symptoms such as olfactory loss or 
sleep disorder were not available.
175
 
 
 
6.1.3 Aspects that may violate validity 
To make a causal inference from an observed association, the validity of the results of a study 
is of similar importance as the aspects mentioned above. The validity of results can be 
summarized into three major components: internal validity, external validity, and statistical 
conclusion validity. Internal validity can be classified into three categories: information bias, 
selection bias, and confounding. External validity, on the contrary, refers to generalizability. 
Statistical conclusion validity is the degree to which conclusions can be drawn from the data 
unless specified otherwise. 
 
 
6.1.3.1 Internal validity 
Internal validity of epidemiological results is subject to validity of measurement (of exposure 
and outcome) that depends on both validity (i.e. absence of systematic error - also known as 
bias) and precision (i.e. absence of random error). Systematic error should be taken into 
consideration in both study design and data analysis, and results need to be interpreted with 
caution. Random error, however, can be dealt relatively easily by increasing the size of the 
study population. 
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Information bias (misclassification) 
In epidemiological research, misclassification of exposure or outcome is a type of 
information bias arising from measurement error that can be further divided into differential 
and non-differential misclassification.
139
  
 
Differential misclassification means that the degree of misclassification depends on other 
variables (status of exposure and/or outcome). As a result, this type of misclassification can 
be problematic and biases (either overestimates or underestimates) the true estimate for an 
observed association, perhaps in case-control and cross-sectional studies especially.
176
. On 
the other hand, a non-differential misclassification means that the probability of being 
misclassified among all study subjects is the same (i.e. at random and not related to other 
variables). It happens, for example, in a case-control study when participants (both cases and 
controls) do not remember their exposure correctly (i.e. recall bias), or in a cohort study when 
the exposure is measured at baseline and independent of the outcome (e.g. risk of disease).  
 
In study I and III, physical activity level and dietary antioxidant vitamins were measured on 
an individual level through validated questionnaires with high quality, which makes 
misclassification of exposure less likely. In study II, tobacco use (both snus and cigarettes) 
was self-reported. It is known that people may underreport such behavior or completely deny 
using tobacco. There may also be a trend that cigarette smokers will quit smoking but initiate 
snus use as a smoking cessation method during a long follow-up period. In study IV, we used 
census data to assess SES, which may have low specificity. Another limitation is that the SES 
was characterized according to the SEI that is mainly classified by occupation, which may not 
represent SES correctly and further reduces specificity. In addition, a large proportion of 
participants were missing information on SEI in the 1980 census. Although we tried to trace 
SES information from the 1970 and 1960 censuses, this may introduce unforeseen 
misclassification. Thus, misclassification of exposure is more likely a concern in study II and 
IV compared to study I and III. However, in observational cohort studies using register-
based data, such misclassification of exposure is independent of disease (i.e. non-differential) 
since the exposure information is collected prospectively, which may in theory lead to a 
dilution of the effect.  
 
One should note the potential misclassification of outcome in register-based research. In this 
thesis, information on PD diagnosis was extracted from Swedish national health registers. 
Postmortem neuropathology information was not available. Neither clinical diagnosis nor 
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medical record was available to the researchers. Hospital discharge diagnoses of PD have 
been validated against rigorous clinical workup, showing a relatively high positive predictive 
value and sensitivity.
165
 Although misclassifications of diagnoses between PD and other 
parkinsonian disorders are common, such misclassification between PD and other 
parkinsonian disorders goes both ways.
165
 
 
In study I, we restricted the definition of PD to include only primary diagnoses in the 
registers for higher accuracy (i.e. positive predictive value). Although sensitivity decreases, 
results were very similar since specificity is almost perfect for PD diagnosis in the registers 
(range between 98.5-100%).
165
 In addition, the positive predictive value for inpatient PD 
diagnosis was found to decline with age, indicating more misclassification in older age 
groups,
165
 whereas studies in this thesis were population-based with no particular age 
restriction. Moreover, Swedish universal healthcare coverage ensures equal access to 
inpatient hospital care and analysis adjusting for hospital visits in study IV showed similar 
results. On the other hand, the validation study by Feldman et al. showed that PD diagnoses 
were less reliable in the CDR,
165
 which could be a consequence of underreporting PD as a 
cause of death.
177-179
 PD diagnoses from outpatient visits were not validated, yet it is 
reasonable to assume a relatively high accuracy for the diagnoses given from specialists. 
Therefore, misclassification of outcome, although likely present, is usually non-differential in 
prospective cohort studies. As a result, the true effect of the exposure on the outcome is 
expected to be stronger than the observed effect. 
 
Selection bias 
Selection bias may occur in the process of selecting participants caused by, for example, 
diagnostic and self-selection biases and differential loss to follow up.
139
 It is one of the major 
concerns in observational studies. However, register-based observational research, to a large 
extent, eliminates such concern, since 1) no recruitment processes are needed, and 2) 
inclusion and exclusion criteria are usually independent of other factors and well predefined. 
Nevertheless, some issues should be noted.  
 
In all studies presented in this thesis, incident PD was defined by at least one record of PD 
diagnosis in the NPR and CDR. Patients with PD identified from primary health care visits 
were not included. In addition, data from outpatient visits did not cover the entire spectrum of 
study period. Therefore, the incidence of PD could be underestimated, especially when 
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outpatient data were not available. If such bias exists, the estimates would be biased towards 
the null.  
 
Looking at the different studies separately, the individuals included in study I were probably 
physically healthier and more health conscious than those who were not included, since they 
participated in the National March event and mailed questionnaires back to researchers. In 
addition, those with missing information on several components of total physical activity 
level were excluded from the study due to difficulty of calculating their daily total MET-
hours. Similarly, in study III, individuals who actively finished FFQs from SMC and COSM 
were included. Study participants who joined the study but had missing information for 
several items on FFQs were lost from analyses. Another limitation of study III is the 
differential response rates between respondents and non-respondents for these two cohorts 
(70% for SMC and 49% for COSM). Selection bias may exist when differential disease status 
and SES cause such differences in response rates in study I and III. However, it is unclear 
whether all these factors are related to PD or not.  
 
A special note should be given to a hypothesis suggested by Ritz and colleagues, which 
highlights a possibility that PD patients may be less nicotine dependent and consequently quit 
smoking more easily than non-PD individuals.
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 Accordingly, in study II, preclinical PD 
patients would quit snus more easily compared to non-PD individuals, and possibly even 
early in their lives, i.e. during adolescence. Then, a pseudo situation (i.e. observed) would 
happen with fewer snus users among preclinical PD patients. As a result, the observed inverse 
association between snus use and PD risk will be a consequence of selection bias due to 
reverse causation. Unfortunately, this hypothesis of nicotine dependence could not be tested 
with the data available in study II, nor could it be examined easily in other prospective 
studies since it is unclear whether the less nicotine-reward mechanism is truly associated with 
PD development. 
 
In study IV, almost every Swedish inhabitant was initially included in the study but those 
below age 30 were excluded from the analysis, based on the assumption that SES was 
unstable before 30 years of age. However, there could be a proportion of individuals with a 
stable SES during follow up in that age group. In addition, SES was assessed based on labor 
market status and individuals with chronically disabling diseases (e.g. patients with early 
diagnosed PD) may therefore be excluded from the study since they tend to be outside the 
labor force. Furthermore, individuals with a high SES might have been more health conscious 
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and actively visited clinics, and were consequently more likely to be given a diagnosis of PD. 
As a result, they would have a higher observed incidence rate of PD compared to those with a 
low SES. On the other hand, individuals with a low SES may have higher morbidity and 
therefore visit healthcare more often than those with high SES. These individuals with low 
SES could also have higher chances to be given a diagnosis of PD. This assumption was 
tested by further adjusting for the number of times visiting hospitals for reasons other than 
PD in a sensitivity analysis. Results were largely comparable to the main analysis, suggesting 
that those individuals were not self-selected. Taken together, selection bias due to differences 
in health seeking behavior by SES is unlikely. Nevertheless, the models in study I - IV were 
all adjusted for educational level as a proxy of SES or health seeking behavior to account for 
such potential bias. 
 
Confounding 
An observed association between two factors can be causal such that one causes another, or 
they share a common cause as a confounding factor (i.e. confounder), or both. A confounder 
should be associated both with the exposure and outcome, but not as an effect of the exposure 
in the causal path way between the exposure and outcome (i.e. mediator), nor as the effect of 
both the exposure and outcome (i.e. collider).
139
 Confounding occurs when exposed and 
unexposed groups differ in this third factor. Without proper adjustment for confounding, the 
association between an exposure and an outcome can be underestimated, overestimated, or 
the association may even be reversed. In epidemiology, causal diagrams (also known as 
Directed Acyclic Graphs, DAGs) have been widely used to identify potential confounders for 
data analysis and to establish a causal relationship visually (Figure 6.1).
181,182
  
 
At the design stage of a study, unlike RCTs where participants and confounders are randomly 
assigned to both exposed and unexposed groups, observational studies are particularly prone 
to confounding. We can, however, avoid or adjust for confounding by applying stratification 
on confounders. In study I, III, and IV, men and women were analyzed separately. In study 
II, there were few snus users among women and the biggest confounder considered was 
tobacco products other than snus. Therefore, primary analyses were restricted to never 
smokers of tobacco products. 
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Figure 6.1 An illustration of concepts in causal inference from a Directed Acyclic Graph 
 
 
We identified confounders based on DAGs and subject knowledge in all studies in this thesis. 
At the analysis stage where confounding information was available, confounding was 
examined through adjustment in regression models. Unmeasured or residual confounding, 
however, can still exist in these studies. For example, although cigarette smoking was 
controlled for through adjustment in regression models in study I and III, it was crudely 
classified into never, current and former smokers. In study IV, smoking information was not 
available but considered as potential explanation for the observed inverse association between 
SES and risk of PD. In addition, genetic confounding of the association between snus use and 
risk of PD was not taken into consideration in study II.  
 
Mediation is another issue worth noting. For example, in study I, BMI was adjusted for as a 
confounder. However, it may also be considered as a mediator between physical activity and 
risk of PD. Adjustment for a mediator changes the interpretation of the results regarding how 
much of the association between physical activity and PD risk can be attributed to the specific 
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covariate. Unfortunately, with available data, we were unable to assess the exact role of BMI 
in this association. 
 
 
6.1.3.2 External validity 
External validity (also known as generalizability) means whether results from a particular 
study can be generalized to individuals in another population. All studies in this thesis were 
based on data from Sweden. Our results may be generalizable to another Scandinavian 
country since they may share similar population characteristics, but it may not be applicable 
to other countries. With regards to study I, given the specific characteristics of the event (i.e. 
National March for cancer prevention fundraising), it is reasonable to believe that participants 
are generally more physically active than others. Therefore, results may not apply to less 
physically active individuals. Study II was restricted to men and results cannot be 
generalized to women. Individuals in study III were in middle to older age groups; therefore 
the results cannot be generalized to younger cohorts.  
 
 
6.1.3.3 Statistical conclusion validity 
A causal effect of statistical inference is conceptually different from causal inference. 
Statistical inference derives from an association being correctly estimated using a 
counterfactual approach (i.e. proper statistical methods), whereas, for example, DAGs 
conceptualize the problem graphically and infer causality. We used mainly the Cox 
regression model in studies included in the present thesis to estimate HR as RR of the 
outcome between exposed and unexposed groups. A few other statistical methods were used 
in different studies for correct estimates of statistical inference and are worth discussing. 
 
Interaction 
Interaction or effect modification can be classified into biological (i.e. causal) and statistical 
interactions. A biological interaction exists when the effect of one factor (i.e. exposure) on 
the outcome is dependent on the presence of another factor (i.e. effect modifier) and when 
some specific mechanism or hypothesis is available. A statistical interaction is an effect-
measure modification that measures changes of effect of the exposure over values of the 
effect modifier under the assumption of no bias, for example, when physical activity has 
differential effects (e.g. positive vs. negative or additive vs. multiplicative) on PD risk in men 
and women. If a biological or social hypothesis is available, statistical interaction should be 
 48 
assessed. In study I, gender was hypothesized as an effect modifier and examined in the 
analyses. In study IV, PD diagnosis was considered an effect modifier and time-varying 
covariate for the association between SES and all-cause mortality, and stratified analyses 
were consequently performed. 
 
Multiple testing 
Multiple testing or multiple comparisons is an issue when many statistical tests are performed 
simultaneously or repeatedly in a set. The probability to reject the null hypothesis incorrectly 
or to observe a rare event by chance will increase, resulting in a false positive or Type I error. 
Multiple testing is common in genetic studies where numerous genetic variants are tested for 
a single trait. Several statistical techniques have been developed to address this issue in order 
to get an unbiased statistical inference. The Bonferroni correction is the most acknowledged 
method requiring a higher significance threshold to reject the null hypothesis.
183
 Although 
correction for multiple testing was performed in study I and the conclusion remained the 
same, in conventional epidemiological research (e.g. studies included in this thesis), 
adjustment for multiple comparisons is usually not necessary. The primary reasons are that 
the number of statistical analyses is limited and they are only performed when there is a 
strong hypothesis.
184
 
 
Relatedness between study subjects 
Another issue one should note is the relatedness between study subjects (e.g. twins in a twin 
pair) in the study. Such dependence between individuals would affect the estimate of the 
standard error. Under the hypothesis that monozygotic twin pairs share 100% and dizygotic 
twin pairs share 50% of their genetic background, using twin data in epidemiological studies 
requires particular attention regarding the statistical analysis. In study II where twin data 
were used, we applied a robust sandwich estimator that takes into account the relatedness in 
data to estimate the ‘correct’ standard errors. In fact, estimates of standard errors with and 
without robust sandwich estimator were similar in this study, owning to a very large sample 
size.  
  
Meta-analysis 
A meta-analysis systematically reviews and summarizes all pertinent evidence on a particular 
research question. In study I, HRs from the study and previous prospective cohort studies on 
physical activity and risk of PD were meta-analyzed with a two-stage method that uses 
extracted aggregate data from each study. On the one hand, this approach provides an overall 
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interpretation and evidence synthesis of all the studies included in the analysis. On the other 
hand, although results were compelling, this method may be subject to different biases.
185
 In 
study II, we performed meta-analysis utilizing individual participant data, where definitions 
of exposures, outcomes and covariates, and study-specific analyses used the same protocol. 
This individual participant data meta-analysis offers several advantages compared to 
conventional aggregate data meta-analysis, and is considered the gold standard approach to 
evidence synthesis.
186,187
 
 
 
6.2 Ethical Considerations 
In medical research, it is very important to ensure the study participant’s privacy and 
individual integrity. This brings trust to the public and reinforces a good relationship between 
the scientific community and public society. In principle, individuals participating in any 
medical research should be contacted and well-informed about the purpose and potential 
consequences of the study. They need to agree and give researchers their consent every time 
their sensitive personal information is collected and used for a specific purpose. According to 
the Swedish law (Lag om etikprövning 2003:460), personal information such as medical 
history is sensitive and all studies based on sensitive data must be approved by an ethical 
committee before the study starts. This ethical committee will judge whether the potential 
benefit of the study outweighs the potential harm to the participants. 
 
It should be noted that all studies conducted in this thesis were register-based and data were 
pseudonymous. All studies were approved by the Ethical Review Board in Stockholm. In 
addition, study participants’ sensitive data were provided by the governmental authority (i.e. 
Statistics Sweden and National Board of Health and Welfare) and reverse identification is 
strictly prohibited and unlikely.  
 
In my opinion, it would be impractical or economically unfeasible to acquire informed 
consent from every single individual, as thousands and even millions of participants were 
included in these studies. Although some findings in this thesis can be potentially sensitive to 
a certain group of participants, I believe the risk of violating participants’ integrity is 
minimal. However, I think the ways of handling sensitive information such as transforming 
data and distributing or discussing findings are more important. This applies, in particular, to 
future epidemiological studies where “big data” have the ability to identify an individual from 
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even anonymous information. Then, data safety will rely more on researcher’s scientific 
quality and ethic judgment for human dignity. Nevertheless, we as researchers should do our 
best to protect the integrity of all individuals in the study. 
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7 INTERPRETATION AND CONCLUSION 
It is never too ambitious to state that I want to defeat PD and I very much hope my work may 
contribute to the prevention of the disease. However, every scientific work, including studies 
in this thesis, can only solve a small piece of the puzzle. It may also be too early to judge the 
true impact of findings yielded from this thesis, but I embrace them simply because they 
answered at least one important research question in each study. Taking into consideration 
ongoing development in the field, I believe the work described in this thesis provide a 
significant fragment of the big picture. 
 
Physical activity may influence inflammation and oxidative stress, which in turn are 
considered putative mechanisms in PD pathogenesis. In the large prospective cohort study 
with nearly 13 years of follow up (study I), people with more than 6 hours per week of 
moderate level of physical activity had a substantially lower risk of PD. Compared with 
previous studies with similar findings, our results illustrate that all physical activity, not just 
physical exercise, can reduce PD risk. This message is particularly important to the public 
both for PD prevention and for the general health benefits of physical activity. Moreover, 
physical activity strategy can be relatively easy and cheap to implement in practice. 
Furthermore, physical activity has been demonstrated to maintain and improve function of 
patients already diagnosed with PD. 
 
A well-known but intriguing finding in PD research is the inverse association between 
cigarette smoking and risk of PD. We used a novel method to examine the potential effect of 
nicotine from smokeless tobacco on PD risk (study II). Compared to the possible beneficial 
effect of smoking, using snus had an even stronger protective effect on risk of PD. 
Importantly, our primary results were restricted to never smokers, largely alleviating any 
potential confounding effect from smoking. However, we need particular caution to interpret 
these results. First, smoking has many adverse health effects and needs to be prohibited. 
Second, although scientific evidence on snus use and health consequences is limited, nicotine 
in itself is highly addictive and advocating snus use is unethical. Moreover, the hypothesis 
about a less nicotine-mediated reward among preclinical PD patients suggests a reverse 
causation bias for the neuroprotective effect of nicotine in PD. Nevertheless, nicotine or other 
components of tobacco leaves may indeed play an important role in PD pathogenesis. 
Therefore, further research is warranted before promoting nicotine as a candidate treatment in 
a PD prevention clinical trial. 
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Intake of dietary vitamin E and β-carotene was associated with a lower risk of PD in two 
large population-based cohorts (study III). Although diet and dietary factors in relation to 
disease risk are of high interest in the society, many findings in this field are not reproducible. 
This is primarily due to the difficulty of diet assessment and the heterogeneity of diet. 
Nevertheless, taking together all the evidence on diet and PD, we conclude that dietary 
antioxidants such as vitamin E and β-carotene are associated with lower risk of PD. To 
explore whether or not they can prevent PD, further studies must move to the molecular level 
and discover the underlying mechanisms. 
 
In the register-based study of almost the entire Swedish population (study IV), we found that 
lower SES was associated with lower risk of PD and with higher all-cause mortality. In 
addition, the impact of SES on all-cause mortality was weaker in PD patients than non-PD 
individuals. The purpose of this study was not only disease risk identification but also to 
generate new hypotheses about risk factors. At this point, with limited information on the 
individual level from the registers, the role of SES in PD prevention remains inconclusive. 
However, the three-fold higher all-cause mortality for PD patients compared to the general 
population needs further attention. 
 
In conclusion, I think that an easily applicable program for PD prevention is not available 
based on current epidemiological evidence on lifestyle factors and PD. The results in this 
thesis, however, provide fruitful insights into a promising way of preventing PD by 
advocating a better lifestyle such as an increase in physical activity and a healthy dietary 
pattern. 
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8 FUTURE PERSPECTIVES 
PD as a chronic aging related disease will pose more social and economic challenges to both 
patients and society as life expectancy is increasing worldwide. Since the essay written by 
James Parkinson exactly 200 years ago, numerous investigations have tried to uncover the 
truth of the disease. If we knew the cause of PD, it would be much simpler. We could either 
focus on drug development or eliminate factors that lead to the disease, or both. 
Unfortunately, we do not know why people develop PD.  
 
Our understanding of PD has increased through scientific and technological development. 
Laboratory data are important for establishing causal pathways between biological candidates 
and the disease, but using lab techniques to identify risk factors for a disease is just like a 
Chinese old proverb “大海捞针”, meaning “searching a needle in the ocean”. Genetic studies 
have provided significant insights into the disease pathogenesis and etiology in the last 
decade. However, until now, identifiable genetic causes are only available for a small 
proportion of PD, while the majority of PD patients are sporadic cases. It may seem 
frustrating at this moment but epidemiological (i.e. observational) evidence, with several 
longitudinal studies, have elucidated various risk factors as well as protective factors for the 
disease. 
 
Identifying risk factors is useful for pinpointing potential biological targets and developing 
targets for disease modifying therapies. Identification of genetic and non-genetic factors, and 
most likely, the gene-environment interplay will be the mainstay to determine the exact 
causality underlying selective dopamine neuron death in PD. Then, clinically definitive 
diagnosis can be made at the true onset of the disease. Eventually, detection of modifiable 
risk factors for PD will enable prevention of the disease. 
 
 
 
 
 
- THE END – 
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11 APPENDIX 
Appendix 1 – Swedish socio-economic classification (SEI)1 
http://www.scb.se/Grupp/Hitta_statistik/Forsta_Statistik/Klassifikationer/_Dokument/SEI-AGG_Eng.pdf 
 
Manual workers Occupations normally organized by LO (The Swedish Trade Union 
Confederation) 
 
11 Unskilled employees in goods production  
Less than 2 years of post-comprehensive school education 
12 Unskilled employees in service production  
Less than 2 years of post-comprehensive school education 
21  Skilled employees in goods production  
2 years or more of post-comprehensive school education 
22  Skilled employees in service production  
2 years or more of post-comprehensive school education 
 
Non-manual employees Occupations normally organized by TCO (The Swedish 
Confederation of Professional Employees) or SACO (The Swedish Confederation of 
Professional Associations) 
 
33  Assistant non-manual employees, lower level  
Less than 2 years of post-comprehensive school education 
36  Assistant non-manual employees, higher level  
Less than 2 but not 3 years of post-comprehensive school education 
46  Intermediate non-manual employees  
Less than 3 but not 6 years of post-comprehensive school education 
56  Professionals and other higher non-manual employees 
At least 6 years of post-comprehensive school education 
57  Upper-level executives  
Upper-level executives in private enterprises or organizations with at least 100 
employees or in public service 
 
Employers  
 
60  Self-employed professionals  
At least 6 years of post-comprehensive school education 
79  Self-employed other than professionals and farmers 
89  Farmers 
 
 
 
 
 
 
1
 Published in Reports on Statistical Co-ordination 1982:4, Statistics Sweden 
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Appendix 2 – Occupational and SEI variables in the censuses 
 
SEI FoB60 
01 Företagare inom jordbruk, skogsbruk m m 
02  Arbetare inom jordbruk, skogsbruk m m 
03  Företagare inom industri-, handels-, transport- och serviceyrken 
04  Företagare inom fria yrken (läkare, advokater m fl) 
05  Företagsledare (anställda) 
06  Tjänstemän (arbetsledare, tekniker, kontors- och handelspersonal m fl) 
07  Arbetare andra än i grupp 2 
08  Anställda inom serviceyrken 
09 Militärer 
10 Personer med ej identifierbara yrken 
11 Studerande (ej förvärvsarb) 
12 Övriga ej förvärvsarbetande eller studerande 
 
SEI FoB70 
01 Företagare inom jordbruk, skogsbruk m m 
02 Anställda inom jordbruk, skogsbruk m m 
03 Företagare inom industri-, handels-, transport- och serviceyrken 
04 Företagare inom fria yrken (läkare, advokater m fl) 
05  Företagsledare (anställda) 
06  Anställda inom tekniska, humanistiska, kontorstekniska och kommersiella yrken 
07  Anställda inom huvudsakligen industri- och transportyrken 
08  Anställda inom vissa serviceyrken 
09  Militärer 
10  Personer med ej identifierbara yrken 
 
SEI FoB80 
11  Ej facklärd i varuproduktion 
12  Ej facklärd i tjänsteproduktion 
21  Facklärd i varuproduktion 
22  Facklärd i tjänsteproduktion 
33  Lägre tjänsteman I 
36  Lägre tjänsteman II 
46  Tjänsteman på mellannivå 
56  Högre tjänsteman/ledande befattningar 
60  Fria yrkesutövare med akademiska yrken 
79  Företagare (exkl. lantbrukare) 
89  Lantbrukare 
91  Oklassificerade anställda 
95  Pensionär 
96  Hemarbete 
97  Studerande 
 70 
98  Deltidsarbete 
99  Uppgift saknas 
 
SEI FoB90 
11  Ej facklärd i varuproduktion 
12  Ej facklärd i tjänsteproduktion 
21  Facklärd i varuproduktion 
22  Facklärd i tjänsteproduktion 
33  Lägre tjänsteman I 
36  Lägre tjänsteman II 
46  Tjänsteman på mellannivå 
56  Högre tjänsteman 
57  Ledande befattningar 
60  Fria yrkesutövare/akademiska yrken 
79  Företagare (exkl. lantbrukare) 
89  Lantbrukare 
91  Oklassificerade anställda 
99  Uppgift saknas 
 
 
 
